Summary
Gilead Sciences, Inc. (GILD) reported its financial results for the quarter and six months ended June 30, 2012. Total revenues showed a notable increase, up 13% year-over-year for the quarter and 15% for the six-month period, primarily driven by strong product sales in its antiviral franchise. The company's flagship products, Atripla and Truvada, continued to perform well, contributing significantly to revenue growth. However, net income for the quarter saw a slight decrease of 5% compared to the prior year, attributed to increased investments in R&D, particularly in liver disease and oncology, and higher interest expenses related to recent debt issuance. This increase in R&D reflects the company's ongoing commitment to pipeline advancement. The company also significantly drew down its cash reserves, largely due to the substantial $11.1 billion acquisition of Pharmasset in January 2012, which is expected to bolster its Hepatitis C (HCV) franchise with the lead compound GS-7977. Operationally, Gilead is advancing several key initiatives. Truvada received FDA approval for pre-exposure prophylaxis (PrEP) for HIV prevention, a significant development for the company's HIV portfolio. In the HCV space, promising data from Phase 2 and Phase 3 studies for GS-7977 were reported, positioning the company for potential regulatory filings. The company also advanced its oncology pipeline with Phase 3 studies for GS-1101. Despite the increased R&D spending and the significant cash outflow for the Pharmasset acquisition, Gilead's liquidity remains a point of focus, with cash, cash equivalents, and marketable securities decreasing substantially from the end of 2011. Investors should monitor the progress of the HCV pipeline and the integration of Pharmasset.
Financial Highlights
54 data points| Revenue | $2.41B |
| Cost of Revenue | $617.35M |
| Gross Profit | $1.70B |
| R&D Expenses | $396.24M |
| SG&A Expenses | $332.50M |
| Operating Expenses | $1.35B |
| Operating Income | $1.06B |
| Interest Expense | $88.42M |
| Net Income | $711.56M |
| EPS (Basic) | $0.47 |
| EPS (Diluted) | $0.46 |
| Shares Outstanding (Basic) | 1.51B |
| Shares Outstanding (Diluted) | 1.56B |
Key Highlights
- 1Total revenues increased by 13% to $2.41 billion for Q2 2012 and by 15% to $4.69 billion for the first six months of 2012, driven by strong product sales.
- 2Net income for Q2 2012 decreased by 5% to $711.6 million year-over-year, attributed to higher R&D investments and interest expenses.
- 3Diluted EPS decreased by 2% to $0.91 in Q2 2012 compared to $0.93 in Q2 2011.
- 4The company completed the acquisition of Pharmasset for $11.1 billion, financed through cash on hand, senior unsecured notes, and bank debt, significantly impacting the cash balance.
- 5Truvada was approved by the FDA for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection.
- 6Gilead continued to advance its Hepatitis C (HCV) pipeline with promising data from Phase 2 and Phase 3 studies for GS-7977.
- 7Cash, cash equivalents, and marketable securities decreased significantly to $2.27 billion as of June 30, 2012, from $9.96 billion as of December 31, 2011, largely due to the Pharmasset acquisition.